EUROFINS
14.12.2021 09:03:17 CET | Business Wire | Press release
Gold Standard Diagnostics continues its response to the threat of the emerging Omicron SARS-CoV-2 variant by providing innovative diagnostic solutions.
The Omicron SARS-CoV-2 variant has raised significant concerns given its rapid spread in South Africa and has now been confirmed in over 40 countries. The variant contains many mutations which may enable the virus to evade the immune response raised by previous infection or vaccination.
With the current uncertainty surrounding the dangers of the Omicron SARS-CoV-2 variant, it is crucial to closely monitor its spread and provide reliable diagnostic solutions for its identification. By now, the variant has already split in two sublineages (BA.1 & BA.2) one of which, nicknamed the ‘stealth Omicron’, does not carry the Spike protein deletion 69/70. This deletion, however, has so far been used as a workaround to identify this variant through a dropout in a widely used RT-PCR assay [1].
Gold Standard Diagnostics Europe now offers a rapid and reliable RT-PCR assay detecting Omicron SARS-CoV-2 variant, including both sublineages. GSD NovaType II SARS-CoV-2 specifically identifies mutations N501Y and K417N, present in Omicron in approximately 1 hour, much faster than genome sequencing methods. The assay is CE-marked and available immediately.
GSD NovaType II SARS-CoV-2 supplements the product range developed in response to emerging SARS-CoV-2 variants, such as GSD NovaType Detect & Select K417N SARS-CoV-2 (RUO), that combines SARS-CoV-2 detection and identification of an Omicron signature mutation in one reaction.
Reference
[1] https://github.com/cov-lineages/pango-designation/issues/361
For more information, please visit Eurofins Technologies website.
About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast-growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005150/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Direct and UnionPay International Will Extend Global Money Movement Network to Billions of Cards in Chinese Mainland3.2.2026 13:00:00 CET | Press release
By connecting Visa Direct’s card network to UnionPay International’s (UPI) MoneyExpress platform, Visa Direct will unlock real‑time1 cross‑border money movement in one of the world’s largest remittance corridors At Web Summit Qatar, Visa (NYSE:V) and UnionPay International (UPI) announced an agreement to enable cross-border money movement into Chinese Mainland through Visa Direct. Once fully rolled out, clients will be able to send cross-border remittances and business-to-consumer payouts to more than 95 percent of UnionPay International debit cardholders in Chinese Mainland, through a single connection. By connecting Visa Direct’s global money movement network to UPI’s MoneyExpress platform, Visa will provide a more seamless, secure, and transparent way for consumers and businesses worldwide to send money into Chinese Mainland, one of the world’s largest remittance destinations. This milestone showcases Visa’s commitment to opening global corridors and extending reliable money movemen
China NMPA Approves Promega MSI Detection Kit as Companion Diagnostic for KEYTRUDA®3.2.2026 13:00:00 CET | Press release
The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is intended for use as a companion diagnostic to identify MSI-High (MSI-H) solid tumor patients for treatment with KEYTRUDA® (pembrolizumab), Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy. This is the first Promega companion diagnostic to receive NMPA approval. “This approval represents a step toward more personalized and effective cancer treatment in China,” says Alok Sharma, Global Clinical Market Director at Promega. “We are proud to collaborate with pharmaceutical companies to deliver global solutions that expand access to innovative technologies and life-saving, effective therapies.” China continues to face one of the world’s highest cancer burdens, with solid tumors representing the vast majority of diagnoses nationwide. Despite advances in oncology care, most patients with advanced so
Rising Global Bullion Market Risks Are Forcing European Investors to Rethink Physical Gold Access3.2.2026 10:35:00 CET | Press release
As volatility reshapes global financial markets, European institutional investors are turning to safe-haven assets. While physical gold remains one of the world's most resilient and attractive store-of-value assets, secure and verifiable access to bullion has become increasingly difficult. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203826775/en/ Illustrative image of physical gold bullion bars. (Photo: AETOSWire) Recent industry developments have placed structural pressure on the gold market. Elevated price levels have heightened concerns around counterfeit bars, fragmented supply chains, and the complexity of cross-border custody. For European institutions operating under strict regulatory oversight, the challenge is no longer whether to allocate to gold — but how to do so safely, transparently, and within established compliance frameworks. To this end, Golden Ark Reserve, operated by Golden Ark General Trading (FZC)
Hyper-Personalization at Scale: Why Brands Must Shift to an Agentic AI Strategy3.2.2026 10:00:00 CET | Press release
As Infobip celebrates 20 years of customer communication innovation, the AI-first company envisions the future of agentic AI Global AI-first cloud communications platform Infobip, celebrating two decades of innovation, predicts an imminent and seismic shift in brand-consumer engagement. Moving away from the current application-to-person (A2P) messaging, Infobip forecasts a widespread shift to an agent-to-person model, eventually leading to a fully autonomous agent-to-agent future by 2030. The Evolution of Engagement Swift AI adoption is driving enterprises toward agentic AI communication models, which drive autonomous customer communications across all touchpoints. This technology enables hyper-personalization across multiple channels, creating highly engaging content tailored to individual needs. Silvio Kutić, Infobip CEO, comments: “How we communicate with brands is constantly evolving. In this new agentic AI world, brands must seize the opportunity to take a holistic approach to com
Corona Cero Unveils Global Roster of Athlete Ambassadors to Champion TIME CERO at Milano Cortina 20263.2.2026 09:00:00 CET | Press release
A First-of-Its-Kind Initiative, In Partnership with International Olympics Committee (IOC), TIME CERO Empowers Athletes to Unwind, Recharge, and Celebrate the Moment Corona Cero Invites Fans to Celebrate Together in Italy with Corona Hotel, Casa Corona, and Other Immersive Activities Corona Cero today unveiled its global roster of brand ambassadors who will champion TIME CERO, the brand’s new initiative created in partnership with the IOC and Athlete365, throughout the Olympic Winter Games. Together, Team Corona Cero will bring the brand’s “For Every Golden Moment” global platform to life, reminding people that meaningful golden moments can happen anytime, anywhere, or in any season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203205858/en/ Team Corona Cero Central to Corona Cero’s commitment as a Worldwide Olympic Partner, TIME CERO is designed to celebrate Olympians and help them relax, stay present, and embrace bala
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom